The Oncology Clinical Trials Program enables patients to access a wide spectrum of newly advanced treatments including immunotherapeutic drugs and targeted therapies for a range of solid and haematological malignancies.
Established in 2003 and led by Associate Professor Gary Richardson OAM, the Department aims to provide compassionate, state-of-the-art care for cancer patients and continued advancements in the prevention, diagnosis, treatment and cure of cancer via a combination of research, education and clinical practice.
A Phase 1b/2 Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-cell Lymphoid Malignancies
Registered Trial Number - BGB-311_GA101_Study_001
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumours
Registered Trial Number - BGB-A317
A Phase 1/1b, Open-Label, Multicentre, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
Registered Trial Number - CPI-444-001
Phase IIIb, Randomized, Study of Multiple Administration Regimes for Nivolumab Plus Ipilimumab in Subjects with Previously Untreated Unresectable or Metastatic Melanoma
Registered Trial Number - CA209742
A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin in First Line Therapy in unresectable Pleural Mesothelioma
Registered Trial Number - CA209743
Haematological / Blood cancers
A Phase II, international, multicentre, randomized, open-label, parallel group study to evaluate the efficacy and safety of CC-486 (oral Azacitidine) alone and in combination with Durvalumab (MEDI4736) in subjects with Myelodysplastic syndromes who fail to achieve an objective response to treatment with Azacitidine for injection or Decitabine
Registered Trial Number - CC-486-MDS-006
A Phase 3, Multicentre, Randomized, Doubleblind Study to Compare the Efficacy and Safety of Oral Azacitidine plus Best Supportive Care versus Placebo plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes
Registered Trial Number - AZA-MDS-003
Circulating Tumour DNA Analysis Informing Adjuvant Chemo in Stage II Colon Cancer (DYNAMIC)
Registered Trial Number - WEHI - ctDNA - 04
A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128 + MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MPL0128 in Women with Advanced, Recurrent, or Persistent Endometrial Cancer
Registered Trial Number - C31004
Kidney / Renal
Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab plus Ipilimumab in Participants with Renal Cell Carcinoma.
The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
Registered Trial Number - CA209800
There are no results to your search.
The keyword you entered is too short. Please use at least three characters.